Cargando…
Risk management in the treatment of type 2 diabetes with pioglitazone
INTRODUCTION: Type 2 diabetes mellitus is one of the most important cardiovascular risk factors. Insulin-resistance represents the common mechanism that leads to type 2 diabetes in obese subjects. Pioglitazone is an insulin-sensitizing agent available for treatment of type 2 diabetes. Large clinical...
Autores principales: | Derosa, Giuseppe, Salvadeo, Sibilla AT |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3048017/ https://www.ncbi.nlm.nih.gov/pubmed/21437118 |
Ejemplares similares
-
Optimizing combination treatment in the management of type 2 diabetes
por: Derosa, Giuseppe, et al.
Publicado: (2007) -
Pioglitazone and metformin fixed-dose combination in type 2 diabetes mellitus: an evidence-based review of its place in therapy
por: Derosa, Giuseppe, et al.
Publicado: (2007) -
Endothelial function, blood pressure control, and risk modification: impact of irbesartan alone or in combination
por: Derosa, Giuseppe, et al.
Publicado: (2010) -
Concomitant therapy with pioglitazone and insulin for the treatment of type 2 diabetes
por: Yamanouchi, Toshikazu
Publicado: (2010) -
Pioglitazone in the Treatment of Type 2 Diabetes: Safety and Efficacy Review
por: Desouza, Cyrus V., et al.
Publicado: (2010)